Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody
Edward B. Reilly(AbbVie (United States)), Andrew M. Scott(Olivia Newton-John Cancer Wellness & Research Centre), Fritz G. Buchanan(AbbVie (United States)), Peter J. DeVries(AbbVie (United States)), Jinming Gu(Brigham and Women's Hospital), Christine Beam(BioPAL (United States)), Jonathan A. Meulbroek(Abbott Fund), Enrico L. DiGiammarino(AbbVie (United States)), Gillian A. Kingsbury(Bicycle Therapeutics (United Kingdom)), Neal Goodwin(Champions Oncology (United States)), Todd Cole(AbbVie (United States)), Yumin Zhang(Uniformed Services University of the Health Sciences), Andrew C. Phillips(AbbVie (United States)), Cherrie K. Donawho(Abbott Fund), Hugh D. Falls(AbbVie (United States)), Joann P. Palma(Abbott Fund)
Cited by 83
Related Papers
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
|Nature|2017|878
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
|Clinical Cancer Research|2007|776
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans
|Proceedings of the National Academy of Sciences|2004|440
Antibody–Drug Conjugates for Cancer Therapy
|Molecules|2020|377
Genetic and molecular analysis of a Caenorhabditis elegans beta-tubulin that conveys benzimidazole sensitivity.
|The Journal of Cell Biology|1989|268